BIOS - バイオスクリプ (BioScrip Inc.) バイオスクリプ

 BIOSのチャート


 BIOSの企業情報

symbol BIOS
会社名 BioScrip Inc (バイオスクリプ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Nursing Services  
業種 ヘルスケア施設_サ―ビス   医療関連(Health Care)
概要 事業概要 バイオスクリップ(BioScrip Inc.)は注入液ソリューションを提供する会社である。同社は、医師、病院システム、専門看護施設、医療従事者、製薬会社と提携して、患者に急性期後ケアサービスを提供する。同社は注入液サービスセグメントで30以上州の約70のサービス場所を通じて事業を運営する。同社が提供する自宅注入液サービスは臨床管理サービスと処方薬の配達を提供する。同社患者の医師の指導と調整によるサービスを提供する。同社の薬剤師、看護師、栄養士、呼吸療法認定士を含む多分野臨床医チームは医師と協力して患者の特定のニーズに適したケア計画を立てる。同社のプラットフォームは患者へコミュニティベースおよび家庭ベースのケア環境を提供する。   バイオスクリプは米国で在宅点滴と在宅医療サ―ビスを提供。患者宅で抗菌薬、栄養、抗がん剤、免疫グロブリンの点滴剤の準備、投与、治療指導のほか、呼吸療法、医療器具を提供。また、処方薬の割引購入プログラム、薬剤給付プラン設計、薬剤使用状況の評価などの薬剤給付管理サ―ビスを行う。   Option Care Health, Inc. provides home and alternate site infusion services. The company was founded in 1996 and is headquartered in Bannockburn, IL.
本社所在地 1600 Broadway Suite 700 Denver CO 80202 USA
代表者氏名 Daniel E. Greenleaf ダニエル・E・グリーンリーフ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 720-697-5200
設立年月日 35125
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 2154人
url www.bioscrip.com
nasdaq_url https://www.nasdaq.com/symbol/bios
adr_tso
EBITDA EBITDA(百万ドル) 40.57200
終値(lastsale) 3.04
時価総額(marketcap) 389260210.88
時価総額 時価総額(百万ドル) 394.38200
売上高 売上高(百万ドル) 725.64700
企業価値(EV) 企業価値(EV)(百万ドル) 954.31900
当期純利益 当期純利益(百万ドル) -122.05800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioScrip Inc revenues decreased 21% to $344.4M. Net loss applicable to common stockholders excluding extraordinary items decreased 37% to $33.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Loss on extinguishment of debt decrease from $13.5M (expense) to $0K Bad Debts decrease from $13.2M (expense) to $0K.

 BIOSのテクニカル分析


 BIOSのニュース

   BioScrip, Inc.'s Shares March Higher, Can It Continue?  2019/06/18 10:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in BioScrip.
   BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue?  2019/06/01 13:31:55 Zacks Investment Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   BioScrip's Option Care Merger on Track, Q1 Loss Narrows  2019/05/09 09:36:00 Zacks Investment Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
   BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2019/05/02 14:33:06 Zacks Investment Research
BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates  2019/05/02 12:35:10 Zacks Investment Research
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
   BioScrip, Inc.'s Shares March Higher, Can It Continue?  2019/06/18 10:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in BioScrip.
   BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue?  2019/06/01 13:31:55 Zacks Investment Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   BioScrip's Option Care Merger on Track, Q1 Loss Narrows  2019/05/09 09:36:00 Zacks Investment Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
   BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2019/05/02 14:33:06 Zacks Investment Research
BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates  2019/05/02 12:35:10 Zacks Investment Research
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
   BioScrip, Inc.'s Shares March Higher, Can It Continue?  2019/06/18 10:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in BioScrip.
   BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue?  2019/06/01 13:31:55 Zacks Investment Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   BioScrip's Option Care Merger on Track, Q1 Loss Narrows  2019/05/09 09:36:00 Zacks Investment Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
   BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2019/05/02 14:33:06 Zacks Investment Research
BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates  2019/05/02 12:35:10 Zacks Investment Research
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (ヘルスケア施設_サ―ビス 米国株 バイオスクリプ BIOS BioScrip Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)